Director of Pharmaceutical R&D, Stefan Grudén, has been invited to present at the Annual Formulation and Drug Delivery Congress being held in London on 29-30 April.
This annual congress is an important event for pharmaceutical companies involved in drug delivery or that are looking to develop and improve new and existing drugs.
-This invitation is a recognition of LIDDS ground-breaking research in drug delivery and the potential that NanoZolid® technology has for the controlled and sustained release of drugs, particularly in the intratumoral treatment of cancer, says Monica Wallter CEO, LIDDS.
At the congress, LIDDS will present the unique NanoZolid® technology and its potential to deliver potent local drug effect with reduced systemic side effects.
-I will be presenting on the development of NanoZolid® and its benefits for the intratumoral delivery of oncology drugs, including in the new and exciting area of immuno-oncology, says Stefan Grudén, Director of Pharmaceutical R&D at LIDDS.
-The presentation will be based around the scientific paper on NanoZolid® that was recently published in the Journal of Drug Delivery Science and Technology. This paper describes how NanoZolid® interweaves the sciences of biomaterials, dosage form design and dedicated cancer research, says Stefan Grudén.
NanoZolid® technology solves one of the major challenges in treating cancer by allowing drugs to be injected directly into a tumor and releasing the drugs for a period of up to six months. This improves drug effectiveness and patient quality of life by allowing high drug loads with reduced side effects and improved compliance.
More information on the Formulation and Drug Delivery Congress can be found at: https://www.oxfordglobal.co.uk/formulation-congress/
The scientific paper "Cold isostatic pressing of hydrating calcium sulfate as a means to produce parenteral slow-release drug formulations" can be found at:
An interview with Stefan Grudén can be viewed on LIDDS LinkedIn page at: https://www.linkedin.com/feed/update/urn:li:activity:6526815112160903168/
For more information, please contact:
Monica Wallter, CEO, +46 (0)737 07 09 22, firstname.lastname@example.org
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology: NanoZolid®. NanoZolid is clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS shares (LIDDS) are listed on Nasdaq First North. Redeye AB, Certifiedadviser@redeye.se, +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit liddspharma.com
This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LIDDS AB via Globenewswire